GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
Switching from Arimidex to Raloxifene worsened hair loss despite using Dutasteride. The user added oral Minoxidil, dermastamping, and RU58841 to their regimen to address the issue.
The user observed that stopping nicotine and caffeine improved their scalp health while using oral finasteride. However, relapsing with caffeine and nicotine caused scalp tightness and inflammation.
User tried dutasteride, topical finasteride, oral minox, dermawounding, saw palmetto, pumpkin seed oil, and ketacozonole for hair loss. Improvement was temporary, now trying RU58841 and seeking help.
Bryan Johnson uses topical dutasteride, minoxidil, and microneedling for hair loss. Users discuss treatment effectiveness and side effects, debating topical versus oral dutasteride efficacy.
The conversation discusses using finasteride, dutasteride, minoxidil, and RU58841, along with a 10,000 graft hair transplant, to prevent magpies from targeting bald men. The title humorously references an eight-year-old's survey on magpies swooping bald men.
The conversation is about a 29-year-old man's progress with hair loss treatment over a year using oral finasteride, topical minoxidil, and dermarolling, which has led to improved hair coverage and increased confidence. Users are encouraging and asking about the timeline of noticeable improvements.
The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.
People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.
The conversation is about seeking recommendations for clinics in Los Angeles that offer dutasteride mesotherapy for hair loss treatment. The user is asking for experiences and suggestions from the community.
The user experienced aggressive hair loss despite using oral finasteride and minoxidil, with additional issues like dandruff and eyebrow hair loss. They are considering switching to oral minoxidil and dutasteride due to scalp inflammation and lack of improvement.
Topical melatonin may help reduce hair loss and increase hair thickness in people with androgenetic alopecia (AGA), with some studies showing positive results. It can be mixed with minoxidil for application, and its effectiveness might be enhanced when used with micro-needling, but results may vary among individuals.
The conversation discusses the effectiveness and skepticism around topical dutasteride for hair loss, with mentions of combining it with other treatments like minoxidil and oral medications. Some users doubt its efficacy due to lack of independent studies and potential conflicts of interest.
Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.
The user is experiencing intense hair shedding all over the scalp after applying pyrilutamide to the hairline and taking oral castor oil. They are also using topical finasteride and latanoprost, but are unsure which treatment is causing the shedding.
The user experienced significant hair thickening and temple hair growth after one year of using finasteride, minoxidil, and weekly dermarolling. They are considering asking their dermatologist about dutasteride.
The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.
PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.
A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.
The user successfully improved their hair from Norwood 3 to 0.5 using finasteride, topical minoxidil, microneedling, and a hair peptide, and plans to maintain it with dutasteride. They are leaving the forum due to emotional distress caused by the community.
PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.
The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.
The user experienced hair improvement after one year using 0.5 mg oral dutasteride, 5 mg oral minoxidil, and ketoconazole shampoo three times a week. They noticed progress after initial shedding and attribute changes to medication adjustments.
The conversation discusses improvements to a platform and mentions hair loss treatments including Minoxidil, finasteride, RU58841, and melatonin. It also highlights the addition of features like Google login, reply by email, keyword extraction, and a term glossary for better understanding of hair-related terminologies.
A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.
The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.
A 31-year-old man with androgenic alopecia is considering treatments like finasteride, minoxidil, and ketoconazole shampoo but is worried about finasteride's side effects. Users recommend starting with finasteride or dutasteride for DHT blocking, suggesting topical solutions to reduce side effects.
The conversation discusses hair loss treatments using oral minoxidil, oral dutasteride, and mesotherapy dutasteride, showing impressive 6-month results. The user wishes these treatments were available in the U.S.